PT-141 vs Melanotan-2: How Bremelanotide and Melanotan II Compare

What are PT-141 and Melanotan-2?

Both peptides are synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH). Melanotan II came first: a lactam-bridged cyclic heptapeptide based on positions 4 to 10 of alpha-MSH, designed at the University of Arizona and described in its first human study as superpotent¹. Its designers took the linear analog melanotan I into tanning studies and the cyclic melanotan II into erectile dysfunction studies².

PT-141 is a later analog of melanotan II developed by Palatin Technologies². It is an agonist at melanocortin receptors, including MC3R and MC4R in the central nervous system³, and under the nonproprietary name bremelanotide it became, by 2007, the only melanocortin agent studied clinically in both men and women⁴. Peptides Only stocks both for laboratory research: PT-141 and Melanotan-2.

PT-141 vs Melanotan-2 at a glance

Structure: one ring, two endings

Melanotan II is Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, with a lactam bridge closing the ring between aspartic acid and lysine¹. PT-141 keeps that ring. The difference is the C-terminus: the molecular formulas differ by one nitrogen, one hydrogen and one oxygen, consistent with a free carboxylic acid in PT-141 where melanotan II carries an amide. The masses are almost identical, about 1025 and 1024 Da.

A one-group change can still matter in pharmacology, but the published record does not isolate what this particular change does. What is clear is that the two molecules were developed for different purposes and then followed very different regulatory paths.

Receptors and mechanism

Melanocortin receptors are a family of five G protein-coupled receptors involved in pigmentation, steroid production and energy balance, and melanotan II remains one of the standard tool compounds for studying them⁷. Its best-known mechanistic experiment concerns appetite: delivered into the brain ventricles of mice, MT-II suppressed feeding in four models of overeating, and the antagonist SHU9119 blocked the effect, showing that melanocortin neurons tonically restrain feeding⁶.

PT-141 research has concentrated on sexual behavior. In rats, systemic PT-141 increased c-Fos activity in hypothalamic neurons, and it produced erections in rats and non-human primates³. In female rats it selectively increased solicitational behaviors without changing lordosis, pacing, motor activity or sexual reward¹². A 2022 review identifies MC4R in the medial preoptic area of the hypothalamus as the most relevant target, with animal data suggesting increased dopamine release⁵.

Human research: from pilot studies to phase 3

Melanotan II's human record is short. A pilot phase I study found skin darkening in two participants, along with mild nausea and spontaneous erections preceded by stretching and yawning¹. A double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction followed: 8 developed erections, with a mean of 38 minutes of high tip rigidity against 3 minutes on placebo⁹. Development then shifted to its analog, PT-141².

PT-141 moved further. Phase 2 trials of an intranasal formulation supported melanocortin-based approaches to erectile dysfunction, and preliminary data in women suggested effects on desire and arousal⁴. The pivotal RECONNECT program, two identical 24-week randomized, double-blind, placebo-controlled trials in 1,267 premenopausal women with HSDD, reported statistically significant increases in desire scores and reductions in related distress versus placebo⁸. The FDA approved bremelanotide as Vyleesi in June 2019¹⁰.

Safety findings compared

Bremelanotide has a systematic safety record. Across about 3,500 participants in 43 studies, nausea occurred in 40.0% of recipients versus 1.3% on placebo, flushing in 20.3% versus 1.3%, and headache in 11.3% versus 1.9%. Focal hyperpigmentation was rare with labeled use but appeared in over a third of participants after up to 16 consecutive daily administrations, and small, transient blood-pressure increases were recorded¹³.

Melanotan II has no comparable dataset. Beyond the small 1990s studies, its safety picture comes from case reports linked to unregulated tanning use: changes in existing moles, new and sometimes dysplastic nevi, and four reported melanomas. The 2017 review that collected these reports stressed that causation is unproven and noted that multiple national health organizations have issued safety warnings about melanotan products¹¹.

Limitations of the evidence

• Melanotan II's human data come from a few small studies and uncontrolled case reports; its mechanistic data are largely from rodents given the peptide directly into the brain.
• Bremelanotide's evidence is strong only for the approved population, premenopausal women with acquired, generalized HSDD¹⁰, and the phase 3 trials were sponsored by its developers⁸.
• Neither peptide is highly selective among melanocortin receptors^5,6, so assigning an effect to one receptor relies on animal pharmacology.
• Research-grade peptides are not drug products. Forensic analysis of seized black-market melanotan II and bremelanotide shows why identity must be confirmed analytically¹⁴.

Choosing between PT-141 and Melanotan-2 for research

PT-141 fits work that needs to connect with the clinical literature on central MC4R signaling and sexual behavior. Melanotan II fits work that uses a broad melanocortin reference agonist, for example in pigmentation or feeding studies, often paired with an antagonist such as SHU9119^6,7.

Every Peptides Only lot ships with a lot-matched certificate of analysis (HPLC purity and mass-spec identity) from an independent lab, published in the COA library; our testing standard and the guide to reading a peptide COA explain what those results mean.